What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Paltusotine demonstrated moderate clinical effectiveness in two pivotal phase 3 trials, with significant improvements in biochemical control (IGF-I normalization) compared to placebo. In PATHFNDR-1, 83.3% of patients maintained IGF-I control versus 3.6% on placebo, and in PATHFNDR-2, 55.6% achieved normalization compared to 5.3% on placebo. However, the absence of active comparator trials against standard treatments limits the assessment of its effectiveness relative to existing therapies.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-effectiveness analyses or ICER estimates were identified in the reviewed sources, making it impossible to evaluate the economic value of paltusotine. The lack of economic modeling data raises significant concerns regarding its cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
While the Acromegaly Symptom Diary (ASD) showed significant improvements in symptom burden, there were no generic HRQoL measures (like EQ-5D) reported, which limits the ability to assess overall quality of life improvements. The absence of caregiver burden data further restricts the understanding of broader impacts on HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Paltusotine exhibited a favorable safety profile in clinical trials, with lower rates of severe adverse events compared to placebo. In PATHFNDR-1, severe AEs were 0% in the paltusotine group versus 10.7% in placebo. However, gastrointestinal AEs were more common in the paltusotine group, which is consistent with the class of drugs.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal trials used placebo as a comparator, which does not reflect the current standard of care for acromegaly treatment. This limits the relevance of the findings for clinical decision-making regarding switching from existing therapies.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a diverse patient population, including both previously treated and untreated patients, which enhances generalizability. However, subgroup analyses revealed small sample sizes, which may limit the robustness of findings in specific populations.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Paltusotine’s oral administration simplifies integration into existing care pathways compared to injectable therapies. The trials indicated that it aligns well with current treatment protocols for acromegaly, requiring minimal adjustments in clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
No data on direct medical costs or resource use implications were found in the reviewed sources, making it difficult to assess the broader economic impact of paltusotine on healthcare systems.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on two phase 3 randomized controlled trials with rigorous designs. However, the small sample sizes and the lack of long-term data limit the robustness of the conclusions.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While the trials provided some sensitivity analyses, the absence of real-world effectiveness data and equity considerations introduces uncertainty regarding the broader impacts of paltusotine in diverse populations.
